SCHEMBL5453610

SCHEMBL5453610

CC(=O)c1ccc(NC(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 13/20 0.77
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2C19 P33261 1/20 0.63
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 4/20 0.59
MAPT P10636 3/20 0.59
GAA P10253 2/20 0.59
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
LMNA P02545 1/20 0.58
RECQL P46063 1/20 0.57
TLR2 O60603 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HPGD P15428 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
HSD17B10 Q99714 1/20 0.56
CASP3 P42574 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5462791 0.88 FLT3 (0.72) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL4234573 0.87 FLT3 (0.72) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5467902 0.86 FLT3 (0.72) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5455065 0.86 MEN1 (0.79) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5450860 0.85 MEN1 (0.78) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5451566 0.85 FLT3 (0.56) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5457467 0.85 FLT3 (0.56) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5455906 0.85 FLT3 (0.74) FLT3MEN1KMT2AALDH1A1MAPT
SCHEMBL5450867 0.85 FLT3 (0.67) FLT3MEN1KMT2ACYP1A2CYP2C19
SCHEMBL5446177 0.84 CFTR (0.60) FLT3MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.